Published online Feb 28, 2007.
https://doi.org/10.4055/jkoa.2007.42.1.106
Agonist for the Control of Apotosis through the Study of Cytokine Expression after Spinal Cord Injury in Rats
Abstract
Purpose
To analyze the cytokines that appear after a spinal cord injury in rats and to determine the agonists that regulate apoptosis.
Materials and Methods
Sixty female Sprague-Dawley rats were anesthetized, and a laminectomy was performed at the 9th thoracic vertebra. The spinal cord injury was induced by dropping a 10 gm weight at a height of 20 mm. The subjects were divided into 5 groups. Group I was administered aminoguanidine, group II was administered GM-CSF, group III was administered riluzole, group IV was administered erythropoietin, and group V was administered methylprednisolone. A control group was administered normal saline. The results were assessed using the Tarlov motor grading method. In 1, 3, 5 and 7 days after the spinal cord injury, the rats were sacrificed and evaluated using the syringomyelic cavity size. Immunohistochemical staining for e-NOS and RT-PCR for XIAP were also performed.
Results
Groups I, III, and V showed significantly different results in terms of the motor recovery and inhibition of increase in the syringomyelic cavity compared with the other groups (p<0.05). The e-NOS activity was observed in groups I, III, and V. The other groups showed almost no e-NOS activity. On the RT-PCR, groups I, III, and V showed significantly different results in terms of XIAP expression with time compared with the other groups.
Conclusion
Steroids, NOS inhibitors and sodium channel inhibitors appear to be important factors for regulating apoptosis in the early stage of a spinal cord injury. Further study will be needed to develop new pharmaceuticals with synergic effects on spinal cord injuries.
Fig. 1
A is longest cavity length and B is transverse cord length over the longest cavity length.
Fig. 2
Methylprednisolon, aminoguanidine, and sodium channel blocker show similar effects but there are significant differences between groups I, III, and V and the Control, II and IV groups.
Fig. 3
(A) control in H-E stain, (B) group V in H-E stain. The cavity size of the control group is three times than group V, methylprednisolon administraton group.
Fig. 4
The largest cavities was noted in the control, II and IV. There are significant differences between the control, II and IV, and groups I, III, and V. These results are similar to the result of the recovery of motor function.
Fig. 5
(A) Noted expression eNOS activity (B) groups I, V and III noted expression eNOS activity.
Fig. 6
The groups administered aminoganidine as a NO inhibitor, riluzole as a sodium channel blocker and methylprednisolone show prominent XIAP expression according with time.
Table 1
Experimental Group
Table 2
Tarlov Score
References
-
Bracken MB. Methylprednisolone and acute spinal cord injury: an update of the randomized evidence. Spine 2001;26 24 Suppl:S55.
-
-
Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997;277:1597–1604.
-
-
Brines M. What evidence supports use of erythropoietin as a novel neurotherapeutic? Oncology (Williston Park) 2002;16 9 Suppl 10:S79–S89.
-
-
Huang CS, Song JH, Nagata K, Yeh JZ, Narahashi T. Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1997;282:1280–1290.
-
-
Song JH, Huang CS, Nagata K, Yeh JZ, Narahashi T. Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther 1997;282:707–714.
-
-
Soy O, Aslan O, Uzun H, et al. Time-level relationship for nitric oxide and the protective effects of aminoguanidine in experimental spinal cord injury. Acta Neurochir (Wien) 2004;146:1329–1335.
-